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ABSTRACT
Major portion of the proteins in a cell refers to their critical roles in metabolism of the living
body. Proteins dysfunction results in the severe disorders which need to be treated in time.
For this, respective proteins can be extracted by the external sources and be supplied to the
human beings. Such medicinal proteins are known as therapeutic proteins (TPs). This review
summarizes some of the key areas about these miracle proteins like their types, classification,
production factories, routes of administration, pharmacokinetics, and potential applications.
Furthermore, challenges and hurdles faced in getting a potential protein drug, its FDA
approval and commercial availability are also highlighted for further research.
Keywords: Recombinant protein, therapeutic protein, production factories, medicinal
proteins, pharmacokinetics.
INTRODUCTION
Proteins have diverse and dynamic role in the living body, building of cell structure,
formation of cellular channels, receptors, catalyzing biological reactions, molecular
transportation and defense mechanisms (Akash et al., 2015). Malfunctioning of this main
component of a living body could lead to harmful diseases. Proteins and small peptides have
been identified for showing great potential for treatment of syndromes and diseases. These
protein-based drugs are named as bio-drugs or biopharmaceuticals (Antosova et al., 2009).
These drug candidates can either replace or inactivate the abnormal protein in a particular
disorder. Moreover, some TPs can act by augmenting the supply of beneficial protein to the
body in order to reduce the impact of disease. That is why, protein-based therapeutics are
constantly being worked upon as novel entities in the life sciences and pharmaceutical
industries (Gharelo et al., 2016).
The history of protein therapeutics begins with isolation of insulin from bovine in
1922 (Leader et al., 2008). Later the insulin (1983) was obtained using the recombinant DNA
technology. This opened the doors for research for developing new therapeutic products and
studies regarding quality regulations ( Kar 2008, Fuh et al., 2016). Until now, more than 150
protein-based drugs have been approved by FDA for various diseases (Ozgur and Tutar 2013,
Lagassé et al., 2017).
Unlike the small biomolecules which are routinely synthesized via chemical methods
in lab, synthesis of TPs and peptides have developed using recombinant DNA technology (
Kar 2008, Akash et al., 2015). Credit to the molecular biology, these protein products can be
expressed and obtained by using genetically modified microbial (bacteria/yeast) or
mammalian cell-based host systems, substantially reducing the downstream stages of the
process (Niazi, 2002). Moreover, using the genetically modified host and protein engineering
techniques, researchers aimed to obtain the protein in its native functional form under
optimized environmental conditions. Till the date, recombinant technologies have contributed
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in manufacturing and commercializing various TPs. These have proven effective in treating
various disorders (Chennamsetty et al., 2009) such as metabolic disorders (Roberts, 2014),
cancer (Adler and Dimitrov, 2012), diabetes (Leader et al., 2008), Phenylketonuria (PKU)
(Russell and Clarke, 1999), anemia, hepatitis (Dipti et al., 2006, Xu et al., 2011), heart (Ho et
al., 2018) and chronic diseases (Kar 2008, Karvar, 2014).
Recombinant TPs possess several advantages over chemical-based proteins. Proteins
possess the property of binding specificity and acting selectivity so there is fewer chance for
the protein drug to affect with the normal biological process and cause the damage to body
(Fei Wen et al., 2009). In addition, proteins are usually well tolerated by the body so TPs
have low potential to induce an immune response. Considering time duration, TPs also
dominate chemical drugs by requiring less time for FDA approval. As the protein drugs are
unique in function, so it is easy for companies to get patent protection for longer period of
time, making protein industry attractive for investors and researchers ( Leader et al., 2008,
Gharelo et al., 2016,).
Classification of Therapeutic Proteins
TPs exhibit a wide range of variations in terms of their properties and therapeutic
applications. Based on these variations, protein-based therapeutics can be differently
categorized such as based on their pharmacological activities, molecular type and molecular
mechanism as shown in Figure 1. On the basis of pharmacological activities, proteins are
categorized into five categories: (i) interfering with the organism or molecule; (ii) providing a
novel activity or function; (iii) augmenting an existing pathway; (iv) replacing an abnormal
or deficient protein; and (v) conjugation to deliver other proteins or compounds (effector
proteins, radionuclide or drugs) to the site of action ( Leader et al., 2008, Buchanan and
Revell 2015).

Figure 1: Classifications of TPs based on their activity and type.
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Another way to classify the TPs is based on their molecular types. Here, these drugs can be
separated into anti-coagulants, enzymes, hormones, interleukins, blood factors, interferons,
engineered protein scaffolds and thrombolites ( Nicolaides et al., 2010, Carter, 2011).
TPs are also congregated on the basis of their molecular mechanism as (a) affecting
covalent bonds with substrates, e.g., enzymes; (b) activity without specific interactions, e.g.,
serum albumin and (c) binding non-covalently to target, e.g., monoclonal antibodies (mAbs)
(Dimitrov, 2012).
On the basis of pharmacological activity of proteins, Leaders categorize proteins in
four groups (Figure 2). Group I and II contain FDA approved proteins which are used in
disease treatments and therapies. While group III and IV are protein drugs which are used as
vaccines and diagnostic agents. Group I is further divided in sub-group Ia, Ib and Ic that refer
to the proteins which replace deficient protein, change a prevailing pathway or do a unique
novel activity, respectively ( Dimitrov 2012, Akash et al., 2015).
Group Ia is specified for proteins needed to treat protein deficiency-based endocrine
dysfunctions like hemophilia A or type 2 diabetes mellitus. Group Ib includes the proteins
that are known to augment body endocrine pathways like interferon-α (Akash et al., 2015).
While the group Ic is dominated by the proteins that are utilized to modify pathophysiology
of human disorders like lepirudin for heparin-induced thrombocytopenia (Adkins and Wilde,
1998, Petros 2008).
Group Ⅰ

Group Ⅱ

(FDA approved proteins)
Group Ⅰa: Replace deficit protein
Group Ⅰb: Change pathway

(FDA approved proteins)
GroupⅡ a: Interfare with signlling pathway

Group Ⅰc: Novel activity

Group Ⅱb: Carrier

Pharmacological
activity
Group Ⅲ
(Vaccines)

Group Ⅳ

Group Ⅲa: For foreign agent

(Diagnostic agents)
Used in diagnostic Assays

Group Ⅲb: For autoimmune disorder
Group Ⅲc: To treat cancer

Figure 2: Classification of TPs on the basis of their pharmacological activity.

Group II contains the proteins with special targeting activity. Proteins in sub-group IIa
are known to interfere with a molecule in the body. These proteins (i.e., monoclonal
antibodies) do so by binding to specific targets and then modifying their function, hence
contributing to stimulate or inhibit a signaling pathway. While the proteins in sub-group IIb
act as a carrier to deliver other proteins or molecules to the targeted site of action (Sutradhar
et al., 2011). The examples include the denileukin diftitox and ibritumomab tiuxetan that are
used for treatment of cutaneous T-cell lymphoma and transformed non-Hodgkin’s
lymphoma, respectively ( Leader et al., 2008, Akash et al., 2015).
Group III is a small class that categorizes protein therapeutic and prophylactic
vaccines. The sub-groups IIIa, IIIb and IIIc contain proteins that act to protect against a
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harmful foreign agent, overcome an autoimmune syndrome or treat cancer, respectively.
Proteins in this class may possess recombinant, purified or synthetic components (Lagassé et
al., 2017). Moreover, this class possesses the potential for production of broad-spectrum
recombinant vaccines against infectious diseases. List of vaccines approved by FDA are
given at: http://www.fda.gov/cber/vaccine/licvacc.htm.
The group IV represents a collection of diagnostic proteins affecting clinical
decisions. These can either act as imaging agents to detect cancer or diagnostic agents to
detect infectious diseases. These proteins are utilized in a wide range of diagnostic assays
including flow cytometry, matrix assisted laser desorption/ionization (MALDI),
immunohistochemistry (IHC), protein microarrays and enzyme linked-immunosorbent assay
(ELISA) (Lin, 2010; Powers and Palecek, 2012).
Most of the protein drugs are commercially available as recombinant while many of
these are in clinical trials to offer differences and better potential over the others. Some of the
newly engineered proteins i.e. multispecific fusion proteins are currently under research and
development (Carter 2011; Dimitrov, 2012).
Production Factories for TPs
Formulation and production of protein therapeutics have to face various technical and
critical challenges from those set by the traditional methods for small molecules or drugs
(Fuh et al., 2016). There are a number of possible protein producing systems including plants,
microbes, fungi, animal cell cultures and transgenic animals.

Figure 3: Examples of the organisms used to obtain TPs.

Proteins smaller in sizes are usually expressed in prokaryotes while larger proteins in
eukaryotes. Transgenic plants are utilized to produce various TPs (Tarafdar et al., 2014, Yao
et al., 2015). Insect systems, mammalian cells and fungi are better for the proteins requiring
glycosylation while prokaryotic systems such as E. coli are preferable for the cost effective,
easiest and fastest expression of TPs and proteins. However, later is not suitable for the
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expression of either large sized and S-S enriched proteins or for the proteins requiring post
translational modifications (PTMs). On the other hand, yeasts can give higher yields of native
glycosylated proteins (~50 kDa) at lower costs (Demain and Vaishnav, 2009). Mammalian
cell lines are most frequently used for the assembly of recombinant mammalian proteins.
Genetically modified animals can also be exploited for the production of TPs which they may
secrete in their blood, urine or milk (Jazayeri et al., 2018, Hunter et al., 2019) (Figure 3).
At present, availability of the information regarding the cell’s physiology, its
metabolism and the factors affecting its protein production and gene expression has endowed
the use of altered factories, namely eukaryotic or prokaryotic, plants or animals (Demain and
Vaishnav, 2009).
Plants
Plant-based protein production systems include non-transgenic plants with
recombinant viruses (Giddings et al., 2000) and transgenic plant cell cultures (Doran, 2000).
Using plants reduces the investment which is required for large scale production of proteins
like enzymes, biopharmaceuticals, technical materials and TPs (Burnett and Burnett, 2020).
Secondary metabolites have major role in chemical defense in plants because of their
antimicrobial and antioxidative properties thus molecular farming can be used for their
production (Tohidi et al., 2017). Use of in-vitro cultured plant cells, tissues or whole plants
for the synthesis of recombinant proteins is called molecular farming (Schillberg et al., 2013).
For both the stable or transient gene expression, Agrobacterium mediated transformation and
particle bombardment have been reported (Van Ooijen et al., 1996). Selective expression of
gene of interest (GOI) for therapeutic protein can also be done by using tissue specific
promoters. These promoters are of greater value because of their higher stability that upon
induction results in greater yield (Hofbauer and Stoger, 2013). In this way, proteins can be
recruited to specific cellular compartments like plastids, endoplasmic reticulum (ER),
cytosol, apoplast or golgi apparatus. Secretory proteins are mainly synthesized by ribosomes
on ER. Plant seed is an ideal machinery for the production of desired pharmaceutical
proteins, cytokines, antibodies, vaccines and so on (Takaiwa et al., 2017). Advantages of
compartment-specific protein expression include extraordinary stability and high yield. A
number of seed specific promoters i.e. endosperm specific promoter, whole seed expression
promoter, transfer cell specific promoter, and embryo expression-promoter have been utilized to
direct the expression to specific tissues (Mohammadinejad et al., 2019).
Recombinant proteins (RPs) can be expressed selectively in in-vitro cultures of cells
from roots, leaves, seeds, or stems. Targeting RPs to plastids results in a good protein yield
but it does not do Post translational modifications (PTMs). That is why RPs can also be
directed to endosperm or embryo in seeds (Mohammadinejad et al., 2019).
Lactuca sativa, Musa paradisiaca, Oryza sativa, Solanum tuberosum, Medicago sativa,
Zea mays, Nicotiana tabacum, Nicotiana benthamiana, Glycine max, Triticum aestivum, Daucus
carota, and Solanum lycopersicum are the preferred systems for therapeutic protein production
(Sack et al., 2015). For biomaterial expression, plants can be genetically modified. Moreover, plant
molecular farming has increased global interest in the production of nanostructures,
pharmaceutical proteins or natural bioactive molecules (Sanchez and Demain, 2010).
Currently available chemical polymerization techniques synthesize variety of polymers as
compared to plants which have access to only 20 amino acids (AA). Another drawback of plant
based proteins is to prepare a sufficient amount of biomaterial to assess its functionality (Moire et
al., 2003). This drawback has significantly been removed with the help of recent advancements in
Biotechnology and gene transfer procedures. Now a days, safe transgenic plant proteins are
available at reasonable prices but there are still the risks for gene escape and public acceptability
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(Bawa and Anilakumar, 2013). It is expected that in near future, plant-based techniques will
undergo advancements making them an efficient alternative for the production of biomaterials
which are normally extracted from animal cells.
Therapeutic protein production in plants possesses many advantages like lower
production cost, lower risks of animal pathogen contamination and feasibility for large scale
manufacturing (Nagels et al., 2012). Apart from this, animal cell expression systems are
costly and prone to environmental changes. Mammalian proteins may not be synthesized in
microbial cultures correctly because of absence of post translational modifications and codon
usage biasness (Fischer and Emans, 2000). Plants also show minor differences in the usage of
codons but these can be compensated by transgene sequence adjustment for the production of
mammalian proteins (Hood et al., 1997). Protein synthesis can also be directed to seed
endosperm to reduce expenses (Wright et al., 2001). Co-extraction of conventional products
like oil or starch can also be done with the required protein of interest (Bai and Nikolov
2001). Extraction of edible vaccines from plants may not be feasible because of the short
shelf life or need for optimizing antigen doses. For this, cheap and simple food processing
procedure can be utilized (Giddings, 2001).
Microbes
Escherichia coli
Escherichia coli is the earliest and most preferred microorganism to express heterologous
proteins, as around 30 % of the approved TPs are currently being produced in it. E. coli is an
expression host of choice in Biotechnology industry for large-scale production of proteins,
particularly non-glycosylated proteins (Terpe, 2006). It is used for the massive production of
TPs because of improved genetic tools and a good understanding of its transcriptional and
translational machinery. This bacterium can accumulate proteins up to 80 % of its dry weight.
Proteins can be exported into periplasm or culture medium by increasing cell wall
permeability or giving osmotic shocks. Promoter system should be strong and regulated so
that they possess low basal expression. The lac, tac, trc promoters can be utilized for the
enhanced productivity of proteins using simple and inexpensive media ingredients (Maksum
et al., 2020).
Easy protein folding mechanisms and bioprocess technologies makes E. coli very
attractive for industrial applications. However, codon biasness in E. coli and absence of posttranslational modifications (PTMs), such as glycosylation, phosphorylation, and proteolytic
processing, limits its use for production of complex recombinant biopharmaceuticals. Several
technological advancements in E. coli expression system have been made, such as production
of novel engineered strains, modification of E. coli to possess capability to glycosylate
heterologous proteins, including full-length glycosylated antibodies (Baeshen et al., 2015).
There are a number of ways by which therapeutic protein production can be improved
in E. coli. Different promoters can be used in different strains for expression regulation.
Growth medium can be changed, temperature could be lowered. Further proteins could be
secreted into medium or periplasmic space or chaperones and foldases could be co-expressed
(Wong et al., 2008). In addition, fusion partner can be added, protein can be denatured or
refolded or protein fragment could be expressed (Maldonado et al., 2007). Toxicity and
acetate production could be reduced by glucose feeding. TPs produced in inclusion bodies are
actually the aggregated, inactive, insoluble proteins possessing inter and intra molecular
disulfide bonds and free cysteines. Inclusion bodies must be removed to obtain fully
functional proteins. Solubilization can be improved by using denaturants and reducing agents
for elimination of S-S bonds (Baeshen et al., 2015). Until 1993, this bacterium was consumed
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for the production of human growth hormone, G-CSF, α, β, γ-interferons and insulin (Swartz
1996). Human IL-3, human IL-6, human BMP-2, murine L1F, murine IL-2, murine SF,
murine IL-5, murine IL-4, human M-CSL, human IL-11, and human M1P-l α are products
which are synthesized in E.coli (Ahmadi and Pfeifer, 2016, Selas Castiñeiras et al., 2018).
Bacillus sp.
Gram-positive bacilli bacteria are also used for heterologous/homologous expression
of enzymes. Using Bacillus sp., recombinant proteins are expressed in its native form.
Further, it exhibits better growth characteristics and robust metabolism without production of
either exo or endo toxins; resulting in cost effectiveness of a therapeutic peptide. Secretion of
proteins into medium eliminates the need for cell disruption, chemical processing and helps
in downstream processing. Bacillus-based protein yields are very high but the formation of
proteases may digest the recombinant protein (Pero and Sloma, 1993). About 96-98%
extracellular protease activity is due to Neutral protease (metalloprotease) and Subtilisin
(serine protease). Until now, six to eight extracellular proteases have been reported. In 2002,
a strain lacking these eight extracellular proteases was developed using genetic engineering
tools (Murashima et al., 2002). Bacillus licheniformis which is an exo-protease lacking host
strain is specifically used for heterologous protein expression. Bacillus brevis is useful for
production of TPs due to production of proteinase inhibitor (Udaka and Yamagata, 1994).
Till present, a number of proteins have been expressed in Bacillus systems including
amylases, xylanases and interleukin-3EGF for the treatment of disorders. Trimeric TNF-α has
been produced by Pseudomonas fluorescens in Pfenex system (Squires and Lucy, 2008).
Yeasts
To overcome the problems in re-folding and glycosylation of proteins in E. coli,
single celled fungi are used for the expression of TPs. Yeast strains are well characterized and
genetically stable. These give high density growth and good protein yield resulting in cost
effectiveness. Its product processing is similar to that of mammalian cells. Post translational
modifications can easily be done in these systems. Yeasts can handle S-S rich proteins, assist
in glycosylation and protein folding (Gerngross, 2004). Rapid productivity using low-cost
media makes the use of these small manufacturing facilities applicable. Pichia pastoris is
used widely for the production of biopharmaceuticals due to understanding of its cell biology
and ability to give clean product (Love et al., 2018). Various other yeast species such as
Saccharomyces cerevisiae have also been utilized for therapeutic purposes. Yeasts have been
proven useful for the production of insulin, glarigine and other monoclonal antibodies
(mAbs) (Mengdai et al., 2020). As a cloning host, S. cerevisiae possesses certain advantages
over bacteria including that it can carry glycosylation and can secrete heterologous proteins
into medium by attaching signal sequences. But glycosylation with S. cerevisiae is
unacceptable for mammalian proteins as O-linked oligosaccharides possess mannose only
(Gellissen et al., 1992). This yeast may also cause immunological problems and possess
reduction in activity and receptor binding over glycosylated N-linked sites. Therapeutic
products which are synthesized using S. cerevisiae include urate oxidase, granulocyte
macrophage colony stimulating factor (GM-CSF), insulin, glucagons, platelet-derived growth
factor, hepatitis B surface antigen and hirudin (Gellissen et al., 1992). Recombinant yeast,
mold, mammalian cells or insects can be used for glycosylation of human chorionic
gonadotropin or erythropoietin (Saul et al., 1985). Fungal TPs show additional carbohydrates
linked to oxygen moiety of threonine or serine (Nunberg et al., 1984). Pichia pastoris has
been genetically modified and is used to produce anti-microbial peptides (AMP). This
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synthetic protein has been successfully isolated and proved useful against E. coli-based
infections (Cao et al., 2018).
Filamentous Fungi
High levels of post translationally modified TPs can be achieved by using filamentous
fungi such as Aspergillus niger (Ward et al., 2004). These fungi are attractive hosts for the
production of synthetic proteins because of their ability to secret protein in its native state. In
filamentous fungi, stable incorporation of the gene of interest (GOI) can be done via plasmids
by its integration as tandem repeats into chromosome. Large quantities of effective antibodies
(Abs) are produced in fungi (Matthews et al., 2017). A. niger is a genetically amenable model
organism for the production of TPs. Despite using different approaches from engineering
secretion pathway, gene knock out and knock in strategies, use of strong promoters and multi
omics-based tactics to the insertion of multiple copies of a gene, yields are lower than desired
in these fungi. Industrial approaches are more effective and direct like reverse genetics,
testing of new expression constructs, engineering novel strains, use of automated fermenters
and optimization of bioprocessing conditions (Zhang et al., 2018).
Trichoderma reesei is an important host for the synthesis of enzymes. It shows high
production efficiency and good yields of cellulases and hemicellulases. Bovine chymosin, Ab
Fab fragments, interferon α2b and IgG Abs has recently been synthesized in this fungus by
engineering protease deletion strains (Belén et al., 2020).
Aspergillus unguis has been used as a host to develop a platform for protein expression using
glyceraldehyde-3-phosphate promoter. High levels of secreted protein were seen using
heterologous signal peptides. Human interferon β is expressed using this expression system
(Madhavan et al., 2017).
Aspergillus oryzae is used for the synthesis of human lactoferrin, mucor rennin and
proteinases (Matthews et al., 2017). Acremonium chrysogenum is effective for the synthesis
of alkaline protease and hirudin (Zhang and Lan, 2018). Chrysosporium lucknowense is a low
protease producing strain giving high yields of (TPs) (Legastelois et al., 2017).
Insects
Insect cells can carry out complex PTMs than can’t be accomplished by other
organisms. Mammalian proteins can be best folded and secreted in soluble form in insects.
Baculovirus is pathogenic for lepidopteran cells and its natural host is army worm. Cultures
of larvae are cheaper and reported to yield more than 400 TPs. Baculovirus-assisted
expression of proteins in insect cell possess a number of advantages like PTMs including
acylation, signal peptide cleavage, myristylation, phosphorylation, prenylation,
carboxymethylation, amidation, proteolytic processing, N- and O-glycosylation and
palmitylation. Polyhedron promoter is used for the expression of foreign gene. This
expression system is also safe because baculovirus can attack invertebrates but not
vertebrates (Dautzenberg et al., 2017).
In 1980, first anti-microbial peptides (AMPs) were separated from pupae of silk
moths; Hyalophora cecropia. Until now, more than 1500 AMPs have been identified in
different species of animals, plants, fungi and bacteria. Insects show natural anti-bacterial
defense mechanism and can be supplied as complex of different AMPs, single peptides or
form of proteins present in livestock (Park et al., 2020). Caenorhabditis elegans is proven
useful for the production of different AMPs against Staphylococcus aureus and Acinetobacter
baumanii and also for rational design of peptidomimetic drugs (Mylonakis et al., 2016).
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Mammalian cells
TPs requiring mammalian PTMs are expressed in mammalian cell-based expression
systems. Chinese hamster ovary (CHO) cells are immortalized for the production of tissue
plasminogen activator (TPA) and erythropoietin (EPO). Mammalian cells are preferred for
the production of mAbs. More than 50 % of the approved synthetic proteins are being
produced in mammalian cell lines (Jazayeri et al., 2018, Hunter et al., 2019). Examples
include baby hamster kidney (BHK) cells, human embryonic kidney (HEK), SF-9, green
monkey kidney cells. Mammalian cell cultures are often preferred because proteins are
synthesized in glycosylated, phosphorylated and folded form with fatty acids added. A
number of TPs such as human chorionic gonadotropin, activase for acute myocardial
infarction, epogen for anemia, human luteinizing hormone (LH), Adalimumab, Trastuzumab,
Bevacizumab, Etanercept, and Rituximab have been synthesized in mammalian cells (Kojima
et al., 2020). A number of anti-cancer TPs have also been produced in mammalian cell
culture
systems.
These
include
Darbepoetin-α (enhances
erythropoiesis),
Lenograstim (stimulates activation of neutrophilic granulocytes), Epoetin-α (enhances
production of RBCs), Ziv-aflibercept (for Metastatic colorectal cancer), Thyrotropin-α (for
Thyroid cancer), Trastuzumab biosimilar (for Gastric cancer and breast cancer), Rituximab
biosimilar (Non-Hodgkin lymphoma) and Interferon-α (for Kaposi’s sarcoma, multiple
myeloma and non-Hodgkin lymphoma) (Lee et al., 2016, Sanchez-Garcia et al., 2016). To
increase productivity of mammalian expression systems, protein-free and chemically defined
media can be used (Legastelois et al., 2017).
Transgenic Animals
Transgenic animals may produce TPs in their blood, milk, plasma, urine, silk worm
cocoons or egg white. These were developed in 1980s using random genomic insertions but
with the passage of time, site directed insertions have become more prevalent (Bosch et al.,
2015). New technologies are based on Clustered, Regularly Interspaced, Short Palindromic
Repeat (CRISPR)/CRISPR associated protein (Cas 9) system (Redel and Prather, 2016) and
transcription activator-like effector nucleases (TALENs) (Ousterout and Gersbach, 2016). A
revolutionary example of using transgenic animals as an expression system is the production
antithrombin (AT). Transgenic animal bioreactor is selected on the basis of a number of
factors like age of sexual maturity of animal, annual dairy production, and reproductive
performance (Konkle et al., 2003). Generation of transgenic animal bioreactor is quite
laborious, complex and requires lengthy timeline but it can synthesize complex proteins
which other systems cannot. Major products of animal-based protein production systems are
factor VIII for the treatment of hemophilia A (Soukharev et al., 2002), ß-lactoglobulin,
albumin, recombinant human protein C, glucosylceramide for Gaucher disease (Tavares et
al., 2016), human hemoglobin, malaria major surface protein (MSP-1) antigen for vaccine
production (Behboodi et al., 2005),and human growth hormone. Recombinant sheep, rabbit,
pigs, cows, goats, mice have been developed as therapeutic protein production system.
Proteins produced in transgenic animals often, possess longer half-life without adverse
reactions.
A summary of advantages, disadvantages and examples of therapeutic protein
production factories is given in Table 1.
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Table 1: Summary of advantages and disadvantages of using different cells or organisms for the production of TPs.
TPs
Production
factories
Plants

E. coli

Bacillus sp.
Yeast

Filamentous
fungi
Insects

Mammalian
cells

Transgenic
animals

Advantages

Disadvantages

Examples

Lower production cost, molecular farming, stable
or transient gene expression, tissue specific
promoters, extraordinary stability, high yield, low
animal pathogen contamination, large scale
manufacturing
Rapid growth, product high yield, cost effective,
easy scale-up process, lac, tac, trc promoters, easy
protein folding mechanisms
Better growth characteristics, robust metabolism,
cost effective, native protein production, high yield
High density growth, good protein yield, cost
effective, suitable for PTMs & S-S rich proteins,
rapid productivity, signal sequences can be
attached
Native protein production, stable GOI
incorporation, genetically amenable

Large amount of biomaterial,
gene escape, public acceptability

Lactuca sativa, Musa paradisiaca, Oryza sativa,
Solanum tuberosum, Medicago sativa, Zea mays,
Nicotiana tabacum, Nicotiana benthamiana, Glycine
max, Triticum aestivum, Daucus carota, and Solanum
lycopersicum
Escherichia coli

Complex PTMs, proper folding, secretion in
soluble form, high-density suspension culture,
multiple genes expression, good yields, S-S bond
formation, anti-bacterial defense system
Undergo PTMs

Pesticides & herbicides
hindrance, lead poisoning,
adverse allergic reactions

Transgenic animal bioreactor, complex proteins
are synthesized, longer

Codon biasness, absence of
PTMs,
Proteases may digest protein

Bacillus licheniformis, Bacillus brevis,

Immunological problems,
reduction in activity, receptor
binding over glycosylated Nlinked sites
Mode of glycosylation

Saccharomyces cerevisiae, Pichia pastoris

Costly, susceptible to
environmental changes,
absence of PTMs & codon
usage biasness
laborious, complex and
lengthy timeline,

Aspergillus niger, Trichoderma reesei, Aspergillus
unguis, Aspergillus oryzae, Acremonium
chrysogenum, Chrysosporium lucknowense
Hyalophora cecropia, Caenorhabditis elegans,
Staphylococcus aureus & Acinetobacter baumanii

Chinese hamster ovary (CHO) cells, baby hamster
kidney (BHK), human embryonic kidney (HEK)
cells, SF-9, green monkey kidney cells
Ostrich, hens, rats, mouse, sheep, cows, rabbit, pigs,
goats
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Vaccines
Charles Amtzen gave the idea of transgenic plant-based vaccines in early 1990s. In
1992, children vaccine initiative was developed to provide cheap edible vaccines for children
(Walmsley and Arntzen, 2000). A number of vaccines for hepatitis B, foot and mouth
disease, and Norwalk virus have been developed (Richter et al., 2000).

Vaccines
Antibodies

Applications
Industrial proteins
Biopharmaceutical
proteins
Figure 4: Multiple applications of Therapeutic proteins.

Pharmacokinetics of TPs
Pharmacokinetic (PK) properties have a significant impact on therapeutic efficacy of
a therapeutic drug so it is very important to focus these during the development of TPs. The
development procedure faces problems in (1) immunogenicity (ability to evoke an immune
response); (2) physiochemical instability (degradation or aggregation) and (3) suboptimal
time of action or circulation half-life ( Fei Wen et al., 2009, Awwad et al., 2018).
Applications
TPs are fast acting medicines that are diverse in their applications (Awwad et al.,
2018). TPs can be used as DNase for pulmonary treatment, erythropoietin for anemia,
interferon-β and interferon-γ for cancer, interleukin-2 for AIDS, insulin for diabetes, PRurokinase for heart attacks, tissue plasminogen activator for strokes, vaccines for Hepatitis B
and monoclonal antibodies (mABs) for diagnosis (Leung 2007) (Figure 3).
Vaccines produced in transgenic plants comprise between 0.01 %-0.4 % of total
soluble protein (TSP) contents. Expression of different proteins depends on the choice of 3′
polyadenylation signals (Richter et al., 2000). Oral tolerance is a hurdle for the development
of oral vaccines. Careful dose managements and adjuvants use might be helpful to avoid such
problems (Santambrogio et al., 2019).
Now, plant-based vaccine is a well understood concept in medicine but their
immunogenicity and efficacy is still in doubt. A number of candidate vaccines that have been
tested in animal models include vaccines against mouth disease virus, Salmonella, E. coli,
Yersinia pestis, bovine, rabbit and canine papillomaviruses, foot and, rabbit haemorrhagic
disease virus, porcine circovirus, mink enteritis and bluetongue virus (Rybicki, 2018).
Antibodies
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For diagnosis, management and treatment of a number of disorders, antibodies have
been used since many years (Stöger et al., 2000). Recombinant antibodies (rAb) as
compared to monoclonal antibodies (mAbs) are easy to detect due to increased biological
activity and reduced immunogenicity. Bacterial rAbs are cheaper but difficult to fold,
modify or assemble correctly while plant-based rAbs produced have long term storage
capacity. The rAbs produced in plants are referred as plantibodies and are successfully
stored in seeds, leaves, and tubers such as potatoes (Frigerio et al., 2000).
Plantibodies were first prepared by Planet Biotechnology, Inc (Mountain View, CA).
Drug CaroRxTM was targeted against Streptococcus mutans, responsible for tooth decay in
humans. CaroRxTM was secretory IgA antibodies taken from transgenic tobacco plant. Field
peas, rice and wheat have been used for the production of Abs and proved helpful for
immune-diagnosis and imaging cancers. Expression of these TPs can be increased 10-100
fold when its location is targeted to ER (Stöger et al., 2000).
Now a day, an important class of medicine has been evolved from therapeutic mAbs
which can be used for the treatment of a number of disorders. Abs consist of two heavy
chains (HC) and two light chains (LC) which are encoded by two different genes that are
specific for assembly of functional recombinant mAb. Currently, it is a big challenge to
produce functional mAbs using plant-based expression systems. In 2018, Ebola virus
monoclonal antibody (EBOV mAb) was synthesized in transgenic tobacco plants which
carried a transcription unit containing HC and LC equal quantities. This gave very good, fully
assembled yield of EBOV mAb in transformed tobacco plants (Lin et al., 2018). In 2018,
human anti-rabies mAbs were also synthesized from transgenic Nicotiana tabacum and
Arabidopsis thaliana transformed using Agrobacterium tumefaciens. Arabidopsis showed 2fold higher protein expression as compared to that of tobacco proving it a useful system for
human anti-rabies mAbs production (Song et al., 2018). In 2019, plant based diagnostic
TM43-E10 Abs were synthesized using OmpD protein of S. typhimurium as antigen in
Nicotiana benthamiana. Plant based Abs showed same antigen binding specificity as
produced by mammalian or microbial cells (Kopertekh et al., 2019).
Industrial Proteins
A number of proteins i.e. β-casein and human milk proteins lactoferrin have been
synthesized industrially in transgenic plant-based bioreactors. These are used as a part of
human infant formulas and baby foods due to antimicrobial properties and enhanced
digestibility (Karav et al., 2017).
Biopharmaceutical Proteins
Glucocerebrosidase and GM-CSF are two of the world’s most expensive drugs and
are produced in transgenic plants. A number of human hormones i.e. somatotropin have been
synthesized in transgenic tobacco plant which has been found useful for treating HIV,
chronic renal failure and Turner syndrome (Tiwari and Sahu, 2017). Proteins encoded from
chloroplast do not possess disulfide bonds so no post-extraction chemical processing is
required. For the treatment of adenosine deaminase (ADA) deficient severe combined
immunodeficiency syndrome (SCID), ADA production has been reported in transgenic plants
(Doshi et al., 2016).
Challenges/bottlenecks for TPs
Although TPs have acquired central point in drug discovery and development with
enhanced safety profiles for human, there are certain issues and challenges that still need to
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be met. A few of the TPs have been reported to cause immune responses and negative side
reactions (Buchanan and Revell, 2015).
Immunogenicity
Recombinant plant-based pharmaceuticals may induce undesirable immune responses
in mammals. As plant derived mAbs possess great variety of glycan structures so
immunogenicity cannot be ruled out in case of systematic delivery (Merlin et al., 2017).
Poor Yield
Despite the availability of a number of filamentous fungi and bacterial strains, yields
of some TPs are very low. Yield can be improved by using strong homologous promoters,
protease deficit host strains, random mutagenesis, and fusion of genes with highly secreted
protein or by increasing gene copy number. Transcription limitations are also found with
filamentous fungi. Increasing gene copy number may tremendously increase protein
expression but not equivalently. Further, heterologous protein can be attacked by fungal
proteases (Legastelois et al., 2017).
Production Expenses
In mammalian cell culture systems, secretion is poor with longer process duration.
Costs of materials are high especially for media. Moreover, manufacturing cost as well as
construction and validation are expensive. In addition, FDA approval is time taking requiring
minimum 4-5 years. These systems can also be easily contaminated by viruses (Arena et al.,
2019).
Aggregated Proteins
In insect cell systems, scientists have to determine patterns of PTMs and expression.
Insect secretion signals are useful for efficient protein production. Intracellular aggregates of
proteins may be formed due to late expression in infection cycle and may lead to improper
folding so earlier harvesting could be useful. Using insects for the expression of TPs also
shows decreased expression which can be enhanced by optimization of time and conditions.
Improper glycosylation has also been a problem. Tissue specific modifications are difficult to
occur (Dautzenberg et al., 2017).
Toxicity
There are some challenges with E. coli system which has to be overcome for good
expression of TPs. Acetate formation can lead to toxicity when we perform with high cell
densities. To avoid this, oxygen level needs to be regulated in the culture. Proteins produced
in the inclusion bodies may be inactive, or require refolding. If a therapeutic protein
possesses many disulfide bonds then its refolding is also difficult. This bacterium produces
non-glycosylated proteins that is why some antibodies are unable to recognize mammalian
antigens (Jenkins and Curling, 1994).
Time Consumption
Transgenic animals require longer period of time to assess protein production along
with the high cost of their maintenance in farms. It takes about 32 months in cows and 28
months in sheep for getting a desired protein (Behboodi et al., 2005).
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To overcome above mentioned problems, therapeutic proteins can be optimized by
increasing understanding about protein rational design, structure-function relationship, and
mechanism of action to enhance functionality and targeting. For future, we recommend
pharmacokinetics information inclusion in drug development as this has been proved helpful
in understanding mechanism of drug action and targeting. In future, neo-sequences in
proteins may harbor immunogenicity problems so there is ultimate need for immunogenicity
mitigation and risk assessment technologies. Further, careful evaluation would be required
for proteins with synonymous codon optimization. Experimental methods with good
throughput and computational technologies have tremendously increased diversity in
therapeutic drug development but some risks are also associated with them which can be
managed with modern technologies (Add reference?).
Commercially Available TPs
Since the approval of recombinant insulin by FDA, there is a considerable increase in
the number of TPs (Leader et al., 2008). Until now, over 400 biopharmaceuticals have
entered the commercialization zone with a valid license for being used for humans in USA
and European Union (EU) from FDA. Among these, a significant portion of ~52 % comprises
the genuine TPs products while the remaining contains the recombinant proteins, bio-similar
products and synthetic peptides (Walsh, 2018). At present, over 1300 peptides and proteins
are in clinical trials (Buchanan and Revell, 2015, Sanchez-Garcia et al., 2016).
Online Resources
A manually curated repository of TPs and peptides approved by Food and Drug
Administration (FDA) named THPdb: Database of FDA-approved peptide and protein
therapeutics (http://crdd.osdd.net/raghava/thpdb/) is available online (Usmani et al., 2017).
CONCLUSION
From this review, it can be conferred that protein engineering is not restricted to
primary sequence changes only but it has improved codon biasness. Codon optimization is
done by altering with synonymous codons for better yield but these can affect protein
function and folding so careful evaluation is required for these TPs. It can also be anticipated
that more proteins will be engineered in the near future with new sequences that are not
present in nature. In future, risks of immunogenicity and side-reactions will also increase
demanding effective methods for immunogenicity risk assessment. Protein engineering in
different production factories has opened up unprecedented opportunities for the development
of convenient, effective and safe TPs. New risks are associated with these opportunities but
these risks can be managed by using recent advancements in Biotechnology.
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